Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery
Vaccines · 25.01.2023 · 11 (2) · 258
DOI: 10.3390/vaccines11020258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 25.01.2023. Verfasst von Ilias Gountas und 7 weiteren Autor:innen. Beteiligte Einrichtung: MSD Greece, 17456 Alimos, Greece. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
The COVID-19 pandemic has caused significant disruptions to healthcare, including reduced administration of routinely recommended HPV vaccines in a number of European countries. Because the extent and trends of accumulated vaccine dose deficits may vary by country, decision-makers need country-specific information regarding vaccine deficits to plan effective catch-up initiatives. To address this knowledge gap in Switzerland and Greece, this study used a previously published COVID-19 recovery calculator and historical vaccine sales data to quantify the cumulative number of missed doses and the catch-up rate required to clear the deficit in Switzerland and Greece. The resultant cumulative deficit in HPV doses for Switzerland and Greece were 24.4% and 21.7%, respectively, of the total number of doses disseminated in 2019. To clear the dose deficit by December 2025, monthly vaccination rates must be increased by 6.3% and 6.0% compared to 2019 rates in Switzerland and Greece, respectively. This study demonstrates that administration rates of routine HPV vaccines decreased significantly among Swiss and Greek adolescents during the COVID-19 pandemic and that a sustained increase in vaccination rates is necessary to recover the HPV dose deficits identified and to prevent long-term public health consequences.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MSD Greece, 17456 Alimos, Greece.
- MSD Switzerland, CH-6005 Lucerne, Switzerland.
- Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ 07065, USA.
- Adelphi Values PROVE, Bollington SK10 5JB, UK.
- Center for Observational and Real-World Evidence (CORE), MSD, 11330 Stockholm, Sweden.
ORCID-Profile: Kunal Saxena
Förderung
- Merck Sharp & Dohme LLC
- Merck Sharp & Dohme LLC
Zitieren
APA
Gountas, I., Favre-Bulle, A., Saxena, K., Wilcock, J., Collings, H., Salomonsson, S., Skroumpelos, A., & Sabale, U. (2023). Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery. Vaccines, 11(2), 258. https://doi.org/10.3390/vaccines11020258
Vancouver
Gountas I, Favre-Bulle A, Saxena K, Wilcock J, Collings H, Salomonsson S, et al. Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery. Vaccines. 2023;11(2):258. doi:10.3390/vaccines11020258
BibTeX
@article{Gountas2023,
author = {Gountas, Ilias and Favre-Bulle, Andrea and Saxena, Kunal and Wilcock, Jessica and Collings, Hannah and Salomonsson, Stina and Skroumpelos, Anastasios and Sabale, Ugne},
title = {Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {2},
pages = {258},
doi = {10.3390/vaccines11020258}
}
EUVIMED